Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.113102 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Xiaomu Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Antibody Engineering Laboratory, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Asthma, Macaca fascicularis, Cytokines, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Severe asthma is a complex and chronic respiratory disease, and current conventional treatments are not effective in controlling the patients' condition. Thymic stromal lymphopoietin (TSLP) is a key regulatory factor in the initiation and maintenance of asthma. Thus, blocking TSLP during allergic inflammation emerges as a promising therapeutic approach; however, novel anti-TSLP therapies remain to be developed. Furthermore, the importance of other signaling molecules, such as IL-4 and IL-13, should be considered. Moreover, to the best of our knowledge, the inhibitory effect of binding upstream and downstream signaling molecules has not been assessed. PURPOSE: This study aimed to develop a novel, humanized anti-TSLP antibody and explore the enhancement in its efficacy when combined with anti-IL-4R antibodies to treat asthma. RESULTS: QX008N, derived from a rabbit antibody platform, exhibits a high affinity for TSLP and superior efficacy in blocking TSLP-induced signaling pathways and inflammation in vitro compared with Tezepelumab. In a cynomolgus monkey asthma model, QX008N ameliorated lung function and reduced the levels of eosinophils and IgE. Moreover, the coadministration of QX008N with anti-IL-4R antibodies enhanced the inhibition of inflammatory mediator production triggered via costimulation in vitro. In mouse asthma models, the simultaneous blockade of TSLP and IL-4R using anti-TL4R and anti-TSLP surrogates surpassed the efficacy of monotherapy. To the best of our knowledge, the therapeutic effect of a combination of anti-TSLP and IL-4R antibodies in an asthma model has not yet been reported. CONCLUSION: These results furnish comprehensive preclinical evidence for QX008N as an innovative anti-TSLP therapeutic agent and provide a preliminary rationale for the development of combination therapies that simultaneously target the TSLP and IL-4R signaling pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Antibody Engineering Laboratory, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
- Qyuns Therapeutics Co., Ltd., Taizhou, Jiangsu, China.
- WLSA Shanghai Academy, Shanghai, China.
- Antibody Engineering Laboratory, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China. Electronic address: zhangjuan@cpu.edu.cn.
- Qyuns Therapeutics Co., Ltd., Taizhou, Jiangsu, China. Electronic address: qiujiwan@qyuns.net.
Zitieren
APA
Wang, X., Kong, Y., Qiu, T., Chen, T., Liu, Y., Shi, G., Sun, Q., Chen, W., Zhang, J., & Qiu, J. (2024). Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113102
Vancouver
Wang X, Kong Y, Qiu T, Chen T, Liu Y, Shi G, et al. Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113102
BibTeX
@article{Wang2024,
author = {Wang, Xiaomu and Kong, Yong and Qiu, Tianquan and Chen, Tao and Liu, Yuzhi and Shi, Gaoyong and Sun, Qiuping and Chen, Wei and Zhang, Juan and Qiu, Jiwan},
title = {Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.113102}
}
EUVIMED